

^d Servicio de Radiología, Hospital Clínico Universitario de Valladolid, Valladolid, Spain
^e Servicio de Anatomía Patológica, Hospital Clínico Universitario de Valladolid, Valladolid, Spain
^f Grupo Emergente de Neumología Intervencionista SEPAR (GEBRYN)
^g Centro de Investigación en Red Enfermedades Respiratorias (CIBERES)

Corresponding author.
E-mail address: blancadevegasanchez@gmail.com
(B. de Vega Sánchez).

<https://doi.org/10.1016/j.arbr.2019.05.017>

1579-2129/ © 2019 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.

Bilateral pulmonary involvement. Non-Surgical options for inflammatory pseudotumor - A case report*



Afectación pulmonar bilateral. Opciones no quirúrgicas del pseudotumor inflamatorio, a propósito de un caso

To the Editor:

Inflammatory pseudotumor is a rare entity that represents less than 1 % of all tumors of the lung.¹ Its radiological characteristics when viewed with standard tomographic techniques overlap with those of other entities,² complicating differential diagnosis, especially in lung cancer.

We report the case of a 49-year-old woman, former smoker with a pack-year index of 2, and a history of hypothyroidism. Her regular treatment was levothyroxine 75 mcg, 1 tablet a day. She attended

the emergency department due to headache following an episode of sinusitis, with no associated respiratory symptoms. The baseline study included a standard chest X-ray, which revealed an incidental finding of a right apical lesion of irregular contours. An initial CT scan was requested that revealed a "rounded tumor mass in the right lung vertex, irregular contours, lobulated and spiculated towards the surrounding parenchyma. Lesion with heterogeneous enhancement with contrast, in extended contact with the posterior and superior apical pleura, measuring about 45 × 42 mm, with no evidence of pleural or extrapleural infiltration or extension; at the apex of the left lung, a small, nodular subpleural, lesion measuring less than 1 cm of dubious significance is observed". In light of these findings, positron emission tomography was performed. This highlighted the presence of this lesion, which was metabolically active with a maximum standardized value (standardized SUVmax) of 27.5, and the lesion in the left upper lobe, which had an SUVmax of 7.5. Bilateral hilar adenopathies were seen in the mediastinum, in




Fig. 1. Computed axial tomography image at diagnosis (A) and after treatment with corticosteroids (B), showing remission of the lesion in the right upper lobe, with some remnants of residual fibrous tracts (arrows). PET-CT image with enhanced uptake in the left pulmonary hilum (C) and in the left upper lobe (D), marked by arrows, reflecting the multilocular involvement of this case.

* Please cite this article as: Delgado Torralbo JA, Masa MP, Crespo EL. Afectación pulmonar bilateral. Opciones no quirúrgicas del pseudotumor inflamatorio, a propósito de un caso. Arch Bronconeumol. 2020;56:49–51.

particular a left hilar conglomerate measuring $3.2 \times 2.1 \times 4.1$ cm with a SUVmax of 14.1 (Fig. 1). Given the high suspicion of malignancy, we decided to conduct a core needle biopsy of the larger lesion, the result of which showed the presence of fibrosis and polymorphous lymphohistiocytic exudate suggestive of an inflammatory process or inflammatory pseudotumor. The molecular study was negative for EGFR gene mutations, but genetic studies were not performed for ALK. Tumor markers (CEA, CA 15.3, CA 19.9, CYFRA-21, squamous cell carcinoma Ag, Pro-GAP, and enolase) were negative. No anemia or thrombocytosis was detected. These results needed to be confirmed by a repeat core needle biopsy, which provided a similar diagnosis. We also performed fiberoptic bronchoscopy, which revealed mucosal thickening of inflammatory appearance in the left lower lobe. Blind bronchial brushing was performed of this region, yielding no neoplastic cells. In the absence of any suggestion of malignancy, and the existence of several lesions that prevented a surgical approach, we decided to start treatment with deflazacor at doses of 1 mg/kg body weight per day for 2 months, tapering to half in the following 2 months, and discontinuing the following month. Three computed axial tomography scans were performed during treatment, showing a progressive decrease in tumor size, as well as the presence of linear tracts of fibrotic scar tissue and traction bronchiectasis in the area, with disappearance of the contralateral nodule.

Inflammatory pseudotumor can occur in any organ, but it mainly affects the lung¹ and occurs more frequently in the first 2 decades of life.² It usually presents as a single, circumscribed mass measuring more than 3 cm, and is more common in the lower lobes.³ It has been described in the literature under different names (plasma cell granuloma, inflammatory myofibroblastic tumor or proliferation, xanthoma, fibroxanthoma, xanthogranuloma, fibrous xanthoma, xanthomatous pseudotumor, plasmacytoma, solitary mast cell granuloma, inflammatory fibrosarcoma),⁴ bearing witness to the complexity, histological heterogeneity, and variable behavior of this entity that, at times, can even be classified as a true neoplasm.⁵ Its etiology is unknown, although there are believed to be several predisposing factors: surgeries, trauma, immune reactions, steroids, radiation therapy, and infections.⁶ The role of an infectious agent seems to be restricted to the early stages, when it triggers a cascade of reactions, through which the tumor develops autonomy.⁷ The microorganisms most frequently associated with inflammatory pseudotumor include mycobacteria, Epstein-Barr virus, *Actinomycetos* and *Mycoplasma*, and some cases have been reported in association with *Corynebacterium equi*, *Escherichia coli*, *Klebsiella*, *Bacillus sphaericus*, *Pseudomonas*, *Helicobacter pylori*, *Coxiella burnetii*,^{4,8,9} herpes simplex virus, and even with HIV infection.¹⁰ Pathological study shows fibrous bands interspersed by irregular layers of lymphocytes, histiocytes, and polyclonal plasma cells.¹¹ Although surgical resection is the treatment of choice,¹² several recent studies have reported rearrangements of the ALK gene on chromosome 2p23 causing aberrant expression in about 50 % of cases.¹³ This suggests that this subgroup could show sensitivity to tyrosine kinase inhibitors such as crizotinib.¹⁴ The only publications supporting their effectiveness are case series,^{6,13} and no trials have been conducted to compare the administration of crizotinib compared to corticosteroids in this subgroup.

The efficacy of corticosteroid therapy varies, and the results reported in the literature^{1,12,14,15} from first-line use in patients who are not candidates for surgery^{1,14,15} (e.g., bilateral presentation) are

limited and inconclusive. Lee et al. reported a similar case in which the response to corticosteroids was excellent, showing no evidence of recurrence after 20 months of follow-up after disappearance of the lesions.¹⁴ Díez et al. obtained similar results after a 30-month course of low-dose corticosteroid therapy.¹⁵ Few cases of bilateral lesions, such as those presented in our patient, have been reported, and the effectiveness and recurrence rate after steroid treatment are unknown, due to the absence of studies in this area.

References

- Reddy RZ, Carter YM, Hsia DW. Pulmonary inflammatory pseudotumor causing collapse responding to corticosteroid therapy. *Respir Med Case Rep.* 2018;3(24):113–6.
- Wang XL, Shan W. Application of dynamic CT to identify lung cancer, pulmonary tuberculosis, and pulmonary inflammatory pseudotumor. *Eur Rev Med Pharmacol Sci.* 2017;21(21):4804–9.
- Agrons GA, Rosado-de-Christenson ML, Kirejczyk WM, Conran RM, Stocker JT. Pulmonary inflammatory pseudotumor: radiologic features. *Radiology.* 1998;206:511–8.
- Narla L, Newman B, Spottswood S, Narla S, Kolli R. Inflammatory pseudotumor. *Radiographics.* 2003;23:719–29.
- Lawrence B, Perez-Atayde A, Hibbard MK, Rubin BP, Dal Cin P, Pinkus GS, Xiao S, Yi ES, Fletcher CD, Fletcher JA. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. *Am J Pathol.* 2000;157:377–84.
- Coffin C, Hornick J, Fletcher C. Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. *Am J Surg Pathol.* 2007;31:509–20.
- Oscos L, Hualde O, Ruperez G, Molins C, Sagaseta U, Molina G. Tumor miofibroblástico en la edad pediátrica. A propósito de 3 casos. *An Pediatr.* 2009;71:331–5.
- Dehner L. The enigmatic inflammatory pseudotumors: the current state of our understanding, or misunderstanding. *J Pathol.* 2000;192:277–9.
- Wood C, Nickoloff B, Todes-Taylor N. Pseudotumor resulting from atypical mycobacterial infection: a histoid variety of *Mycobacterium avium-intracellulare* complex infection. *Am J Clin Pathol.* 1985;83:524–7.
- Braun B, Cazorla A, Rivas C, Gargolas M, Fernández-Guerrero M. Inflammatory pseudotumor of the spleen in a patient with human immunodeficiency virus infection: a case report and review of the literature. *Ann Hematol.* 2003;82:511–4.
- Matsubara O, Tan-Liu NS, Kenney RM, Mark EJ. Inflammatory pseudotumors of the lung: progression from organizing pneumonia to fibrous histiocytoma or to plasma cell granuloma in 32 cases. *Hum Pathol.* 1988;19(7):807–14.
- Fabre D, Fadel E, Singhal S, de Montpreville V, Mussot S, Mercier O, Chataigner O, Darteville PG. Complete resection of pulmonary inflammatory pseudotumors has excellent long-term prognosis. *J Thorac Cardiovasc Surg.* 2009;137:435–40.
- Butrynski JE, D'Adamo DR, Hornick JL, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. *N Engl J Med.* 2010;363:1727.
- Lee MH, Lee HB, Lee YC, Rhee YK, Lee EJ, Chung MJ, Jin GY, Kweon EY, Park SJ. Bilateral multiple inflammatory myofibroblastic tumors of the lung successfully treated with corticosteroids. *Lung.* 2011;189(5):433–5.
- Díez JM, Fernández E, Sáez G, Cañizares F, Marín JL, López de la Osa A. Multifocal inflammatory pseudotumor of the lung with good response to corticoids. *Arch Bronconeumol.* 1998;34(2):102–4.

José Antonio Delgado Torralbo*, María Pavón Masa,
Estefanía Luque Crespo

Hospital Universitario Virgen Macarena, Sevilla, Spain

Corresponding author.
E-mail address: joseantoniodelgadotorralbo@gmail.com
(J.A. Delgado Torralbo).